Lv2
198 积分 2021-11-15 加入
Abstract 6940: A first-in-class PD-L1/B7-H3/VEGF tri-specific ADC achieves enhanced preclinical antitumor efficacy through direct cytotoxicity, immune checkpoint blockade and VEGF inhibition
4小时前
已关闭
Abstract 5655: YL252: A dual-functional PD-L1/VEGF-targeting ADC integrating immunotherapy, anti-angiogenesis, and cytotoxicity
4小时前
求助中
Abstract 6536: A novel multi-modal PD-L1xVEGF-ADC, HX116, could be a new potent candidate treatment for pan-solid tumors
5小时前
求助中
KEYNOTE-585 Fails While Matterhorn Succeeds in Gastric Cancer: What Lessons Can We Learn?
4天前
已完结
Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study
4天前
已完结
299P First-line osemitamab plus nivolumab and CAPOX for advanced G/GEJ cancer (TranStar102) – Updated efficacy analysis of cohort G by CLDN18.2 and PD-L1 expression from a phase I/II study
10天前
已完结
946P Updated efficacy of ASKB589 plus CAPOX/PD-1 inhibitor in first - line metastatic G/GEJ adenocarcinoma: Phase Ib/II study
11天前
已完结
First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial
14天前
已完结
First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial
17天前
已完结
23P SHR-A2009, a HER3-targeted ADC, plus bevacizumab (Bev) for pretreated EGFR-mutated non-squamous (EGFRm nsq) NSCLC: A phase Ib/II study
18天前
已完结
皖公网安备34019202002308
